These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8904108)

  • 1. A comparison of in vitro activity of ten oral antimicrobial agents against respiratory tract pathogens.
    Platsouka E; Constantoulaki S; Dimitropoulos N; Niha M; Pierros N; Dimopoulou H; Paniara O
    J Chemother; 1995 Nov; 7 Suppl 4():58-60. PubMed ID: 8904108
    [No Abstract]   [Full Text] [Related]  

  • 2. Antimicrobial activity of the new macrolide flurithromycin against Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis and Staphylococcus aureus.
    Nord CE; Lindmark A; Persson I
    J Chemother; 1989 Jul; 1(4 Suppl):203-4. PubMed ID: 16312369
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro activity of moxifloxacin against community respiratory pathogens in Qatar.
    Elshafie SS; Al-Kuwari J
    Int J Antimicrob Agents; 2004 Sep; 24(3):309-10. PubMed ID: 15325441
    [No Abstract]   [Full Text] [Related]  

  • 4. Activity of oral beta-lactam antimicrobial agents versus respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the era of antibiotic resistance.
    Doern GV
    Otolaryngol Head Neck Surg; 2002 Dec; 127(6 Suppl):S17-23. PubMed ID: 12511856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.
    Sahm DF; Brown NP; Draghi DC; Evangelista AT; Yee YC; Thornsberry C
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):8-15. PubMed ID: 18931466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective.
    Sahm DF; Brown NP; Thornsberry C; Jones ME
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):16-24. PubMed ID: 18931467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro activity of trovafloxacin in 238 respiratory pathogens].
    Alarcón T; Domingo D; Prieto N; Sánchez S; López-Brea M
    Rev Esp Quimioter; 1998 Mar; 11(1):47-51. PubMed ID: 9795289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
    Jacobs E; Dalhoff A; Korfmann G
    Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
    Blondeau JM; Suter M; Borsos S
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN; Fritsche TR; Sader HS; Stilwell MG
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000].
    Melo-Cristino J; Fernandes ML; Serrano N;
    Acta Med Port; 2001; 14(5-6):459-68. PubMed ID: 11878155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
    Sader HS; Gales AC; Granacher TD; Pfaller MA; Jones RN;
    Braz J Infect Dis; 2000 Oct; 4(5):245-54. PubMed ID: 11063556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002.
    Mendes C; Kiffer CR; Blosser-Middleton RS; Jones ME; Karlowsky JA; Barth A; Rossi F; Andrade S; Sader HS; Thornsberry C; Sahm DF;
    Clin Microbiol Infect; 2004 Jun; 10(6):521-6. PubMed ID: 15191379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
    Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
    J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results.
    Biedenbach DJ; Jones RN; Lewis MT; Croco MA; Barrett MS
    Diagn Microbiol Infect Dis; 1999 Apr; 33(4):275-82. PubMed ID: 10212755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of cefodizime against respiratory pathogens.
    Wise R; Andrews JM; Ashby JP
    J Antimicrob Chemother; 1990 Nov; 26 Suppl C():9-12. PubMed ID: 2127417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program.
    Beekmann SE; Heilmann KP; Richter SS; García-de-Lomas J; Doern GV;
    Int J Antimicrob Agents; 2005 Feb; 25(2):148-56. PubMed ID: 15664485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The postantibiotic effect of azithromycin on respiratory pathogens].
    Diculencu D; Andrews JM; Boswell FJ; Wise R
    Rev Med Chir Soc Med Nat Iasi; 1996; 100(3-4):128-34. PubMed ID: 9455450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of oral antibiotics against respiratory tract pathogens in Spain.
    Calvo A; Amores R; Valero E; Fuentes F; Gómez-Lus ML; Prieto J;
    Rev Esp Quimioter; 2003 Dec; 16(4):436-43. PubMed ID: 14961138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.